HRT Just Changed

The protocol emerges directly from the expert’s synthesis of the WHI saga. He explains that the typical patient he sees seeking menopausal hormone therapy is in her late 40s or early 50s—exactly the age group that was underrepresented in the original WHI. The expert details how, when researchers finally sorted outcomes by age, a signal of protection emerged for women in their 50s: 31% lower all-cause mortality, no increase in heart disease, while the harms seen in the original trial were concentrated in women who started HT a decade or more past menopause. The 2024 study and Cochrane review reinforce that women starting HT within 10 years of menopause or before 60 derive benefit without the cardiovascular penalty seen in older initiators. The FDA’s updated recommendation now explicitly states that treatment should not be automatically limited to a short course at the lowest dose; instead, the decision about starting, dose, and duration should be made at an individual level. The expert underscores that this is not a blanket endorsement—HT still carries risks like breast cancer and venous thromboembolism—but that the risk–benefit calculus shifts dramatically depending on when it is begun. He sees the FDA’s move as removing an institutional barrier that had prevented many women from even having the conversation with their doctors, and encourages shared decision-making grounded in the new evidence.

The expert walks through how the WHI’s initial results triggered a public health panic. The primary endpoint—heart attacks and heart-related deaths—was 29% higher in the HT group, stroke risk 41% higher, pulmonary embolism more than doubled, and breast cancer rose 26%. Colorectal cancer and hip fractures were lower, but the bad news dominated. The FDA’s response was a dramatic warning label, and usage dropped from about one-quarter of women over 40 to just 5% or less. Now, the FDA has admitted that approach was wrong. It removed the broad cardiovascular and cancer warnings (except for an endometrial cancer risk warning for estrogen-only products in women without a hysterectomy). It also removed the instruction to prescribe the lowest dose for the shortest time and instead says treatment decisions should be individualized. Most importantly, it now explicitly endorses starting therapy before age 60 or within 10 years of menopause to optimize the benefit–risk ratio. This change brings the FDA into line with clinical guidelines from groups like the American College of Obstetricians and Gynecologists, which had already recognized the importance of timing. The statement from ACOG noted that the change removes a barrier and shifts power to women through shared decision-making with their doctors. The expert underscores that this is a watershed moment for women who had been scared away from a therapy that, used correctly, can strengthen bones, protect the heart, and relieve debilitating symptoms.

The expert explains that the WHI investigators made a design decision that skewed the results: because they were primarily interested in heart disease, they deliberately recruited older women (ages 50–79, average 63) to get events sooner. Menopause typically occurs around age 51, so the women who most often seek help—those in perimenopause or early postmenopause in their late 40s and early 50s—were underrepresented. When outcomes were then broken down by age, a striking pattern emerged. For women aged 50–59, all-cause mortality was 31% lower in the HT group compared to placebo, suggesting protection. For women 60–69, there was no difference. For women 70–79, the trend reversed toward harm, though it wasn’t statistically significant in that subgroup. A study from fall 2024 (mentioned as ‘this fall’) added weight, finding no elevated heart disease risk for women under 60 starting HT, while risks were elevated for those over 70. A Cochrane review reached the same conclusion: starting HT within 10 years of menopause or before age 60 was associated with benefits for mortality and heart disease. This body of evidence reframes HT not as inherently dangerous but as a treatment whose risk/benefit profile is exquisitely sensitive to the age of initiation.

The expert outlines that the key lies in the state of the arteries at the time estrogen is introduced. When women are younger, any atherosclerotic plaques that exist are at an earlier, less complex stage. At this point, estrogen exerts protective effects on the endothelium and vascular function, which may explain why premenopausal women have lower rates of heart disease than men and why heart disease risk accelerates after menopause. In older women, however, plaques have often progressed to more advanced, vulnerable stages. In that context, adding estrogen might have the opposite effect—potentially promoting instability or thrombosis, which could lead to clinical events like heart attacks or strokes. This biological model is why the FDA now explicitly recommends starting therapy in women under 60 or within 10 years of menopause. Even though research is ongoing, the concept of a ‘window of opportunity’ for cardiovascular benefit from estrogen is now widely accepted in the field, and it directly informs the new clinical guidance.